Evaluation of Sexual Function With Adjunctive Lumateperone in Patients With Major Depressive Disorder.
Anita H Clayton, Willie R Earley, Susan G Kozauer et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of adjunctive lumateperone 42 mg/day on sexual function in adults with major depressive disorder (MDD) who had inadequate response to antidepressant therapies. Among 480 patients, those receiving lumateperone showed a significant improvement in sexual functioning, with a least squares mean difference of 2.7 in the Changes in Sexual Functioning Questionnaire Total score at Day 43 compared to placebo.
Key findings
- 82.5% of patients had sexual dysfunction at baseline.
- Lumateperone+ADT improved CSFQ-14 Total score by LSMD=2.7 at Day 43.
- Patients with baseline sexual dysfunction saw a greater improvement (LSMD=3.1).
- Significant improvements were noted in both pleasure and arousal/excitement domains.
Why it matters
Understanding the impact of treatments on sexual function is crucial for patient care, especially in those with MDD who often experience sexual dysfunction. This study suggests that adjunctive lumateperone may improve sexual functioning without exacerbating issues related to sexual health.